In conclusion, our study suggests that sphingolipid metabolism may play a role in VEN resistance in CD14 positive monocytic phenotype AML by influencing the expression of BCL2 family genes, primarily BCL2 and BAX. This evidence concerns the gene BCL2 and acute myeloid leukemia.